3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)-5-(3-oxo-[1,4,2]dioxazinan-2-ylmethyl)-benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)-5-(3-oxo-[1,4,2]dioxazinan-2-ylmethyl)-benzamide
• 英文别名: 3,4-difluoro-2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-5-[(3-oxo-1,4,2-dioxazinan-2-yl)methyl]benzamide
• 化学式: C₁₉H₁₇F₃IN₃O₆
• 分子量: 567.26
• InChiKey: AVGMZZMVFXLTSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  109
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  2-氟-4-碘苯胺 在 sodium periodate 、 四氧化锇 、 sodium cyanoborohydride 、 碳酸氢钠 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 3-羟基-1,2,3-苯并三嗪-4(3H)-酮 、 三氟乙酸 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 、 水 、 乙腈 为溶剂， 生成 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)-5-(3-oxo-[1,4,2]dioxazinan-2-ylmethyl)-benzamide
  参考文献：
  名称：

  Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent

  摘要：

  The MAP kinase pathway is one of the most important pathways involved in cell proliferation and differentiation, and its components are promising targets for antitumor drugs. Design and synthesis of a novel MEK inhibitor, based on the 3D-structural information of the target enzyme, and then multidimensional optimization including metabolic stability, physicochemical properties and safety profiles were effectively performed and led to the identification of a clinical candidate for an orally available potent MEK inhibitor, CH4987655, possessing a unique 3-oxo-oxazinane ring structure at the 5-position of the benzamide core structure. CH4987655 exhibits slow dissociation from the MEK enzyme, remarkable in vivo antitumor efficacy both in mono-and combination therapy, desirable metabolic stability, and insignificant MEK inhibition in mouse brain, implying few CNS-related side effects in human. An excellent PK profile and clear target inhibition in PBMC were demonstrated in a healthy volunteer clinical study. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.062

文献信息

• 5-Substituted-2-Phenylamino Benzamides as MEK Inhibitors
  申请人：Isshiki Yoshiaki

  公开号：US20090233915A1

  公开（公告）日：2009-09-17

  An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R 1 , R 2 , R 3 , R 4 , and X are the same as defined in the present patent application].

  本发明的目标是提供一种具有强烈MEK抑制活性、在体内稳定且可溶于水的化合物，可用作增生性疾病的预防或治疗剂。本发明的化合物及其药学上可接受的盐由以下公式（1）表示：[其中，R1、R2、R3、R4和X的定义与本专利申请中定义的相同]。
• 5-Substituted-2-Phenylamino Benzamides as Mek Inhibitors
  申请人：Isshiki Yoshiaki

  公开号：US20100197676A1

  公开（公告）日：2010-08-05

  An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R 1 , R 2 , R 3 , R 4 , and X are the same as defined in the present patent application].

  本发明的目标是提供具有强MEK抑制活性、在体内稳定且可溶于水的化合物，这些化合物可用作增生性疾病的预防或治疗剂。本发明的化合物及其药学上可接受的盐由以下公式(1)表示：[其中R1、R2、R3、R4和X的定义与本专利申请中定义的相同]。
• 5-Substituted-2-phenylamino benzamides as MEK inhibitors
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US07745663B2

  公开（公告）日：2010-06-29

  An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R1, R2, R3, R4, and X are the same as defined in the present patent application].

  本发明的目标是提供一种表现出强烈的MEK抑制活性并在体内稳定且可溶于水的化合物，可用作增生性疾病的预防或治疗剂。本发明的化合物及其药学上可接受的盐由以下公式(1)表示：[其中R1、R2、R3、R4和X的定义与本专利申请中定义的相同]。
• 5-substituted-2-phenylamino benzamides as MEK inhibitors
  申请人：Isshiki Yoshiaki

  公开号：US08575391B2

  公开（公告）日：2013-11-05

  An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R1, R2, R3, R4, and X are the same as defined in the present patent application].

  本发明的目标是提供具有强MEK抑制活性、在体内稳定且可溶于水的化合物，可作为增生性疾病的预防或治疗剂。本发明的化合物及其药学上可接受的盐由以下式子（1）表示：[其中R1、R2、R3、R4和X的定义与本专利申请中的定义相同]。
• 5-SUBSTITUTED-2-PHENYLAMINO-BENZAMIDE AS MEK INHIBITOR
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1780197A1

  公开（公告）日：2007-05-02

  An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R1, R2, R3, R4, and X are the same as defined in the present patent application].

  本发明的目的是提供具有强 MEK 抑制活性、在体内稳定且可溶于水的化合物，这些化合物可用作增殖性疾病的预防或治疗剂。 本发明的化合物及其药学上可接受的盐由下式（1）表示： [其中 R1、R2、R3、R4 和 X 与本专利申请中所定义的相同]。